Gå til produktoplysninger
a clear glass vial containing off-white powder, labeled ‘PT-141 10 mg – Batch No.004 – 29-06-2025,’ sealed with a gray rubber stopper and matte cap, positioned on a neutral beige background
1/2
PT-141 10mg vial

PT-141 10mg vial

€32,50 EUR
Inkl. skatter.

                                             NOT FOR HUMAN CONSUMPTION

PT-141, also known as Bremelanotide, is a synthetic peptide that acts as a melanocortin receptor agonist. It was initially developed as a tanning agent but was later found to have significant effects on sexual arousal and dysfunction. Unlike PDE5 inhibitors like Viagra or Cialis, PT-141 works through the central nervous system (CNS) rather than directly affecting blood flow.

Mechanism of Action

PT-141 primarily targets melanocortin receptors (MC3R and MC4R) in the brain, which are involved in sexual arousal. By stimulating these receptors, it enhances libido and sexual response independently of nitric oxide pathways, making it effective even for individuals who do not respond to PDE5 inhibitors.

Uses and Benefits

  1. Treatment of Sexual Dysfunction

    • FDA-approved for HSDD (Hypoactive Sexual Desire Disorder) in premenopausal women under the brand name Vyleesi.
    • May be used off-label for erectile dysfunction (ED) and low libido in men.

  2. Potential Performance Enhancement

    • Increases sexual desire, arousal, and response time in both men and women.
    • Can improve spontaneity in sexual activity, unlike PDE5 inhibitors that require timing.

  3. Possible Other Uses (Under Research)

    • Potential appetite suppression and weight regulation benefits.
    • May play a role in pain management and immune system regulation due to melanocortin receptor involvement.

Dosage and Administration

  • Typically administered as a subcutaneous injection in the abdomen or thigh.
  • Standard dose: 1.75 mg for HSDD in women (self-injected at least 45 minutes before sexual activity).
  • Effects can last 6 to 12 hours, with residual effects up to 24-48 hours.

Side Effects

  • Common: Nausea, flushing, headache, injection site reactions.
  • Less Common: Increased blood pressure, darkening of skin (hyperpigmentation), yawning.
  • Rare but Serious: Cardiovascular risks (caution in individuals with hypertension or heart conditions).

Comparison to PDE5 Inhibitors

Feature PT-141 (Bremelanotide) PDE5 Inhibitors (Viagra, Cialis)
Mode of Action Central nervous system Peripheral vascular (blood flow)
Effect on Libido Direct increase in desire No effect on libido itself
Onset Time 30-60 minutes 30-60 minutes (Viagra), 15-30 mins (Cialis)
Duration 6-12 hours (sometimes longer) 4-36 hours (Cialis longest)
Administration Injection Oral tablet
Use for Women Yes, FDA-approved for HSDD Not approved

Legality and Availability

  • FDA-approved as Vyleesi for HSDD in women.
  • Available via prescription in the U.S.
  • Often sourced off-label from peptide vendors for research purposes

 

References

  • iamond, L. E., Earle, D. C., Garcia, W. D., & Spana, C. (2006). Bremelanotide: An overview of preclinical and clinical data. Journal of Sexual Medicine, 3(5), 716-726.

  • Kingsberg, S. A., Clayton, A. H., Pfaus, J. G., & Simon, J. A. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. Obstetrics & Gynecology, 134(4), 753-765.

  • Safarinejad, M. R. (2008). Evaluation of the efficacy, safety, and characterization of intranasal bremelanotide in the treatment of erectile dysfunction: A prospective, randomized, double-blind, placebo-controlled, parallel-group trial.Journal of Sexual Medicine, 5(4), 866-873.